However, the addition of anti-VEGF antibody bevacizumab to paclitaxel plus carboplatin as first-line treatment failed to extend the progression-free survival (PFS) and overall survival (OS) of RM-NPC patients [6]. Here, VEGFA is linked to nasopharyngeal carcinoma.